D 824

Drug Profile

D 824

Alternative Names: D824; GZD 824

Latest Information Update: 10 Aug 2016

Price : $50

At a glance

  • Originator Guangzhou Institutes of Biomedicine and Health
  • Class Benzamides; Heterocyclic compounds; Piperazines; Small molecules
  • Mechanism of Action Bcr-abl tyrosine kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Chronic myeloid leukaemia

Highest Development Phases

  • Preclinical Chronic myeloid leukaemia

Most Recent Events

  • 10 Aug 2016 Chemical structure information added
  • 26 Jul 2016 D 824 is available for licensing in North America, European Union (excluding China) as of 26 Jul 2016. (http://english.gibh.cas.cn)
  • 01 Jan 2012 Preclinical trials in Chronic myeloid leukaemia in China (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top